Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological.
Sitting at the center of genetics and metabolism, Lucy Therapeutics is leading the change in how we think about mitochondria and the intersecting pathways that play critical roles in human health and disease, particularly those of the central nervous system including Parkinson’s disease and Rett syndrome. Lucy Therapeutics is a private biotechnology company in Cambridge, MA, founded by Amy Ripka, PhD., in 2017, that is dedicated to unraveling the complex and interrelated biological processes driving mitochondrial dysfunction and addressing them to slow and stop the diseases they cause. The Lucy Therapeutics compounds also reduced levels of α-synuclein, the major constituent of Lewy bodies, which accumulate and are a pathological hallmark of PD. “The grant and support from the Michael J. Lucy Therapeutics also received two Golden Tickets from Biogen and Bristol Myers-Squibb to support work at Lab Central. Specifically, LucyTx-1209 and LucyTx-1212 are designed to target one of the functions of the protein complex F1F0-ATPase, which acts within the ETC. The development of LucyTx-1209 and LucyTx-1212 resulted from Lucy Therapeutics’ proprietary research strategy and platform. [BUSINESS WIRE](https://www.businesswire.com/))--Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced promising preclinical data for multiple compounds in its lead program for Parkinson's disease, during an oral presentation at the Michael J. We did not observe any significant safety issues with the use of LucyTx-1209 or LucyTx-1212 in pre-clinical laboratory or rodent studies, so we will now focus on studies to select the best candidate to advance for clinical trials.” "Lucy Therapeutics wants to create a world in which mitochondrial-involved neurological diseases like Parkinson’s or Rett syndrome can be halted when diagnosed,” said Amy Ripka, Ph.D., founder and CEO of Lucy Therapeutics. The scientists recognized a key target for drug discovery and development within the mitochondria’s electron transport chain (ETC), which is a known driver of multiple dysfunctions specific to Parkinson’s disease. “The high selectivity and potency of two of our lead small molecule agents, LucyTx-1209 and LucyTx-1212, in inhibiting a target we believe is at the nexus of several mitochondrial pathways contributing directly to Parkinson’s disease represents a significant advance for our mission to develop first-in-class therapies for neurological diseases”